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Abstract
This study was conducted to investigate the hypocholesterolemic effect of simvastatin (30 mg/kg BW) and antioxidant effect of coenzyme Q10
(CoQ10, 15 mg/kg BW) or green tea (5%) on erythrocyte Na leak, platelet aggregation and TBARS production in hypercholesterolemic rats treated
with statin. Food efficiency ratio (FER, ADG/ADFI) was decreased in statin group and increased in green tea group, and the difference  between
these two groups was significant (p<0.05). Plasma total cholesterol was somewhat increased in all groups with statin compared with control. Plasma
triglyceride was decreased in statin group and increased in groups of CoQ10 and green tea, and the difference between groups of statin and green
tea was significant (p<0.05). Liver total cholesterol was not different between the control and statin group, but was significantly decreased in the
group with green tea compared with other groups (p<0.05). Liver triglyceride was decreased in groups of statin and green tea compared with the
control, and the difference between groups of the control and green tea was significant (p<0.05). Platelet aggregation of both the initial slope and
the maximum was not significantly different, but the group with green tea tended to be higher in initial slope and lower in the maximum. Intracellular
Na of group with green tea was significantly higher than the control or statin group (p<0.05). Na leak in intact cells was significantly decreased
in the statin group compared with the control (p<0.05). Na leak in AAPH treated cells was also significantly reduced in the statin group compared
with groups of the control and CoQ10 (p<0.05). TBARS production in platelet rich plasma was significantly decreased in the groups with CoQ10
and green tea compared with the control and statin groups (p<0.05). TBARS of liver was significantly decreased in the group with green tea compared
with the statin group (p<0.05). In the present study, even a high dose of statin did not show a cholesterol lowering effect, therefore depletion
of CoQ10 following statin treatment in rats is not clear. More clinical studies are needed for therapeutic use of CoQ10 as an antioxidant in prevention
of degenerative diseases independent of statin therapy.
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Introduction9)
HMG coA reductase inhibitor, statin is recognized as one of 
the most popular drugs for lowering cholesterol in human. 
Among US adults aged ≧ 40 years with hypertension, 14.5% 
are taking statin medication in NHANES (1999-02) (King et al., 
2007) and an increasing number of the population in Korea are 
using statin therapy. Besides the cholesterol lowering effect, 
statins are known to be effective in prevention of cardiovascular 
diseases such as stroke (Mastuno et al., 2004), myocardial 
infarction (Susic et al., 2003) and hypertension (Zacco et al., 
2003). Beneficial effects of statin further include preservation 
of bone mineral (Staal et al., 2003), prevention of beta amyloid 
accumulation (Pentaceska et al., 2002) and cell apoptosis (Kaneta 
et al., 2002). However, statin associated adverse effects also 
cannot be ignored. The most serious and frequent side effects 
from statin use are muscle dysfunctions such as myalgia and 
cardiomyopathy which may be associated with the function of 
coenzyme Q10 (CoQ10) in mitochondria electron transport 
system (ETS). CoQ10 enables the oxidative phosphorylation in 
the bioenergetic system via its action in mitochondrial ETS of 
active muscles. Statin therapy has been reported to deplete 
coenzyme Q10 which shares the cholesterol biosynthetic path-
way. Statin therapy caused a reduction of plasma CoQ10 and 
ubiquinol-10 along with decreased total and LDL cholesterol 
(Mabuchi et al., 2005). Statin also depleted CoQ10 in platelets 
and lymphocyte in rats (Littarru et al., 2007) and hepatocyte 
mitochondrial CoQ10 level in vitro (Tavintharan et al., 2007). 
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Table 1. Composition of experimental diets (%)
Ingredient Control Statin Statin+CoQ10 Statin+Green 
Tea
Cholesterol based diet
Casein
a) 20 20 20 20
L-methionine
a) 0.3 0.3 0.3 0.3
Lard 9.0 9.0 9.0 9.0
Soybean Oil 1.0 1.0 1.0 1.0
Choline chloride
b) 0.2 0.2 0.2 0.2
Vitamin mix
c) 11 1 1
Mineral mix
d) 3.5 3.5 3.5 3.5
Sucrose 20 20 20 20
Corn starch 39.3 39.3 39.3 39.3
Cellulose
f) 55 5 -
Cholesterol
f) 0.5 0.5 0.5 0.5
Cholic acid
f) 0.2 0.2 0.2 0.2
Simvastatin
g) - 30 mg/Kg BW 30 mg/Kg BW 30 mg/Kg BW
Coenzyme Q10
h) - - 15 mg/Kg BW -
Green Tea powder
i) -- - 5
Total(%) 100.0 100.0 100.0 100.0
a)  Teklad,  Harlan  Madison  WI,  USA 
b)  Junsei  Chemical  Co.,  Ltd.
c)  Vitamin  mixture(mg/100g):  Thiamine  HCl  60.0,  Riboflavin  60.0,  Pyridoxine  HCl 
70.0,  Nicotinic  Acid  300.0,  D-Calcium  Pantothenate  160.0,  Folic A c id  2 0 . 0 , 
D-Biotin 2.0, Vit. B12 0.1, Vit. A 80.0, Vit. D 3 0.25, Vit. K 0.5, Sucrose 99247.15
d) Mineral mixtuer(g/100g): CaHPO4 50.0, NaCl 7.4, K3C6H5O7․H2O 22.0, K2SO4
5.2, MgO 2.4, Manganous carbonate(43-48%Mn) 0.35, Ferric citrate(16.7%Fe) 
0.6,  Zinc  carbonate(70%  Zn)  0.16,  Cupric  carbonate(53-55%Cu)  0.03,  KIO3 
0.001,  Na2SeO3․5H2O  0.001,  CrK(SO4)2․12H2O  0.055,  Sucrose  11.804
f) S i g m a  C h e m i c a l C o . ,  U S A
g)  Choongwae  Pharm.  Co.,  Korea
h)  Yungjin  Pharm.  Co.,Ltd
i)  Jeju  Agri.  Devel.  Tech.  Exten.  Center
Statin user with myopathic symptoms had revealed lower 
muscular CoQ10 concentration (Lamperti et al., 2005) and 
supplementation of CoQ10 reverses the decreased plasma CoQ10 
and alleviated the myalgic symptom following statin therapy 
(Nawarskas, 2005). Besides the function in the respiratory chain, 
the reduced form of CoQ10 (CoQH2), ubiquinol in plasma 
membrane scavenges radicals generated in metabolic processes, 
protecting cell membrane from oxidative damage and depletion 
of coenzyme Q10 leads to a loss of antioxidant capacity. Dha-
nasekaran et al. (2005) proposed a lipophilic antioxidant, CoQ10 
participates regeneration of alpha-tocopherol and ascorbate in the 
plasma membrane and prevents lipid peroxidation. The extent 
of oxidative membrane damage has been measured by hemolysis 
test (Draper et al., 1969) or erythrocyte Na passive leak which 
can be increased upon exposure to oxygen generating system 
(Garay et al., 1983). Platelet aggregation and its release reaction 
were affected by the condition of oxidative stress (Naseem et 
al., 1999), and platelet superoxide and TXA2 generation were 
reduced by plant antioxidant (Ryszawa et al., 2006). Green tea 
polyphenol, eipigallo catechin gallate (EGCG) prevented eryth-
rocyte membrane from lipid peroxidation in vitro (Saffari et al., 
2004) and green tea catechins inhibit AAPH induced conjugated 
diene formation and LDL oxidation in vitro (Osada et al., 2001)
We proposed to test the cholesterol lowering effect of statin 
in hypercholesterolemic rats and to test whether dietary supple-
mentation of coenzyme Q or green tea can compensate the 
deplete state of antioxidant following statin therapy, giving better 
antioxidant index on erythrocyte membrane and platelet aggre-
gation. 
Materials and Methods 
Animals and diets 
Forty of eight week old Sprague Dawley rats (Orient Bio Co 
Ltd, Gapyung, Korea) were divided into four groups and fed 
the following diets: 0.5% cholesterol based control diet; control 
diet plus 30 mg/kg simvastatin; statin plus 15 mg/kg BW CoQ10; 
statin plus 5% green tea powder (Table 1). Rats had free access 
to water and were housed in individual cages in a room 
maintained at 20-25℃ with a 12-hour dark-light cycle. After 4 
weeks ad libitum feeding, blood samples were obtained by 
cardiac puncture into heparinized vacuum tubes, and platelet 
aggregation and erythrocyte Na efflux were performed with fresh 
blood. Liver samples were prepared for microscopic examination 
and plasma and liver samples were stored at -70℃  for later 
assays.
Plasma and liver lipid assays 
Plasma total cholesterol and methanol for triglyceride were 
assayed using enzymatic kits (Asan Pharmaceuticals, Korea). 
Liver lipids were extracted by a modified Folch method (Folch 
et al., 1957). One gram of liver tissue was homogenized for 5 
min in 6 ml of Folch solution [chloroform(2):methanol(1)] and 
2 ml H2O. After centrifugation for 10 min, the lower phase which 
contains liver lipids was separated. Lower phase of lipid fractions 
after being treated with triton X-100: chloroform (25 µl:475 µl) 
for total cholesterol and methanol for triglyceride was assayed 
using enzymatic kits (Asan Pharmaceuticals, Korea). 
Platelet aggregation 
Platelet aggregation was measured using a Chronolog Whole 
Blood Aggregometor (model 500-Ca, Havertown, Pennsylvania, 
USA), of which the instrumental principle is based on the 
increase in impedance (Ω) across two platinum electrodes as 
platelet aggregation proceeds. The whole blood was diluted with 
isotonic saline (1:4) to give platelet concentration of appro-
ximately 200,000 platelets/µl. Adenosine diphosphate (ADP, 2 
µM) was added to initiate aggregation, and three readings of 
impedance changes were averaged for each rat. 
Erythrocyte Na-leak 
Sodium leak is defined as the sodium efflux through passive 
diffusion with inhibition of ouabain sensitive Na-pump and 
furosemide sensitive Na-K cotransport and can be increased upon 300 Statin and antioxidant CoQ10
Table 2. Supplementation effects of simvastatin, CoQ10 and green tea to 
cholesterol based diet on growth rate and feed intake
Control Statin Statin+CoQ10 Statin+Green Tea
Cholesterol based diet
Final BW (g) 363.3 ± 26.8 350.6 ± 29.3 361.8 ± 29.1 369.6 ± 18.1
ADG
1) (g/d) 2.87 ± 0.6 2.42 ± 0.9 2.80 ± 0.8 3.07 ± 0.6
ADFI
2) (g/d) 17.3 ± 1.0 16.9 ± 1.6 18.1 ± 3.6 16.3 ± 1.1
FER
3)*0 . 1 7 ± 0 . 0 4
ab 0.14 ± 0.03
b  0.15 ± 0.03
ab  0.19 ± 0.04
a
LW/BW
4) (%) 4.2 ± 0.3 4.3 ± 0.6 4.2 ± 0.5 4.3 ± 0.5
1)  ADG:  Average  daily  gain
2) A D F I :  A v e r a g e  d a i l y  f e e d  i n  t a k e  
3)  FER:  Food  Efficiency  Ratio
4)  LW/BW:  Liver  weight  to  final  rat  body  weight 
Values  are  mean ± SD  of  10  rats.
*  Values  in  the  same  row  not  sharing  the  same  superscript  differ  (p＜0.05)
membrane damage of erythrocyte after exposure to free radical 
generating system such as AAPH [2,2’-azobis(2-Amidino-pro-
pane) dihydrochloride] 
Blood was centrifuged at 1,000 × g for 10 min, and the plasma 
and buffy coat were removed. Red blood cells were washed 5 
times with a cold isotonic washing solution [150 mM choline 
chloride, 10 mM Tris-MOPS (morpholinopropane sulfonic acid), 
pH 7.4 at 4℃], centrifuging at 1,000 × g for 5 min after each 
wash. The final erythrocyte pellet was resuspended in the choline 
chloride washing solution to give 40-50% hematocrit. The hema-
tocrit was measured. A 5 µl aliquot of the suspended erythrocyte 
was added to 5 ml of 0.02% acationox (a metal free detergent, 
Scientific Products, McGaw Park Illinois, USA) to be used for 
determination of Na concentrations.
Erythrocyte suspensions of 2 ml each were added to 40 ml 
Na efflux medium (150 mM choline chloride, 10 mM glucose, 
1 mM ouabain, 1 mM furosemide, 10 mM  Tris-MOPS pH 7.4 
at 37℃) with and without 1 mM AAPH, then mixed gently and 
aliquoted to 12 tubes. Tubes in duplicate were transferred to an 
ice bath after incubation in 37℃ shaking water bath for 0, 10, 
20, 30, 40 and 50 min. Tubes were centrifuged at 1,000 × g for 
5 min, then the supernatants were removed and measured Na 
concentration. Na leak (mmole/l rbc/hour) is calculated from 
efflux slope which increases upon exposure to free radicals.
Calculations (Kang et al., 1990)
Na µg/(ml×min)×60 min×mmole/23 mg×[44 ml-(4 ml×hct)/ 
(0.0041×hct)]×(mg/1000 µg) 
= mmole/l rbc/hour (Na leak) 
Na µg/(ml×min)×mmole/23 mg×101/hct×(mg/1000 µg) 
= mmole/l rbc (Intracellular Na) 
Hemolysis
Autohemolysis was performed by modified method of Draper 
et al. (1969); determining the extent of hemolyis with the 
absorbance at 415 nm using a spectrophotometer.
Liver and PRP TBARS production 
Platelet rich plasmas (PRP) were obtained after centrifuging 
whole blood at 300 × g for 10 minutes. PRP and liver samples 
were preincubated at room temperature for 48 hours before 
determining TBARS. Thiobarbituric acid reactive substance 
(TBARS) was determined according to a modified Yagi’s method 
(Yagi, 1976). Plasma lipids were precipitated with phospho-
tungstic acid and TBARS in the pellet were measured at 
excitation 515 nm, emission 553 nm with a fluometer (Kontron 
model SFM 25) using 1,1,3,3 tetraethoxypropane (Sigma- 
Aldrich) as a standard. 
Histological examination 
Two parts of liver samples each rat were obtained from 4 rats 
each group. After being washed with saline, samples were fixed 
in 10% formalin for 48 hours and dehydrated in xylene for 18 
hours. Samples were then embedded in paraffin and cut into 4-5 
um cross section. Tissues were stained with hematoxylin-eosin 
for microscopic observation. 
Statistical analysis 
Values were analyzed using the SAS package (SAS, 1994). 
Analyses of variance were conducted in a completely randomized 
block design. Duncan’s multiple test was applied to compare 
individual means when F-value was significant (p<0.05). 
Results
Weight gain and food efficiency
Weight gain and food efficiency are shown in Table 2. The 
final body weight was decreased in the statin group compared 
with the control and increased in groups with CoQ10 and green 
tea to the level of the control, but no statistically difference. Food 
intake was not different among groups, but FER decreased in 
statin group and increased in green tea group, showing statistical 
difference between these two groups (p<0.05). 
Plasma and liver cholesterol and triglyceride
Plasma total cholesterol (Table 3) were somewhat increased 
in the statin group compared with the control, and CoQ10 or 
green tea further increased these levels, but was no statistical 
difference among groups. HDL-cholesterol was decreased in the 
simvastatin group and increased in groups with CoQ10 and green 
tea. Plasma triglyceride was decreased in the statin group and 
increased in groups of CoQ10 and green tea, and the difference 
between groups of statin and green tea was significant (p<0.05). 
Liver total cholesterol (Table 3) was not different between the 
control and statin group, but was significantly decreased in the 
group with green tea compared with other groups (p<0.05). Liver 
triglyceride was decreased in groups of statin and green tea 
compared with the control, and the difference between groups Yang Hee Kim et al. 301
Table 3. Supplementation effects of simvastatin, CoQ10 and green tea to 
cholesterol based diet on plasma and liver lipids.
 Control Statin Statin+
CoQ10
Statin+
Green tea
Cholesterol based diet
Plasma (mg/㎗)
Total-cholesterol 171.6 ± 69.6 182.9 ± 52.5 194.6 ± 60.7 199.4 ± 46.7
HDL- cholesterol 26.9 ± 5.1 25.7 ± 6.2 28.4 ± 5.6 29.8 ± 4.3
Triglyceryde* 73.4 ± 15.8
ab 66.6 ± 16.3
a  85.7 ± 20.7
ab  94.8 ± 29.5
b
Liver (mg/g)
Total-cholesterol* 12.2 ± 3.7
a 12.0 ± 1.8
a 11.4 ± 3.2
ab  7.4 ± 3.7
b
Triglyceryde* 15.2 ± 3.0
a 12.8 ± 2.4
ab 14.9 ± 3.3
ab 11.5 ± 2.6
b
Values  are  mean ± SD  of  10  rats
*  V a l u e s  i n  t h e  s a m e  r o w  n o t  s h a r i n g  t h e  s a m e  s u p e r s c r ip t  d i f f er  (p＜0.05)
Table  4. Supplementation effects of simvastatin, CoQ10 and green tea to 
cholesterol based diet on platelet aggregation
Control Statin Statin+
CoQ10
Statin+
Green tea
Cholesterol based diet
Initial Slope(Ω/min)
1)  7.7 ± 1.8  7.6 ± 1.9  7.5 ± 1.1  6.8 ± 1.8
Maximum(Ω)
2) 10.3 ± 2.2 11.3 ± 2.0 10.2 ± 2.1 12.0 ± 2.8
1) Maximum aggregation in ohm at the point where platelet aggregate is dissociated
2) I n i t i a l  s l o p e  i s  t h e  o h m  c h a n g e  f o r  t h e  f i r s t  o n e  m in u t e  o f  a g gregation
Values  are  mean ± SD  of  10  rats
Table  5. Supplementation effects of simvastatin, CoQ10 and green tea to 
cholesterol based diet on hemolysis and erythrocyre Na leak
Control Statin Statin+
CoQ10
Statin+
Green tea
Cholesterol based diet
Hematocrit (%) 44.4 ± 2.7 43.9 ± 1.1 42.5 ± 1.9 44.2 ± 2.4
Hemolysis (%) 7.5 ± 1.1 8.3 ± 1.1 8.1 ± 1.8 8.2 ± 1.7
Intracellular Na
1)
(mmole/ℓ rbc)
1.98 ± 0.39 2.09 ± 0.42 2.25 ± 0.72 2.60 ± 0.67
Na Leak
2) (mmole/ℓ rbc/hour) 
Intact 0.24 ± 0.11 0.14 ± 0.10 0.20 ± 0.08 0.20 ± 0.05
AAPH* 0.26 ± 0.11
a 0.15 ± 0.04
b 0.26 ± 0.07
a 0.21 ± 0.06
ab
1)  Intracellular  Na  is  for  intact  erythrocyte
2)  Na  leak  is  erythrocyte  Na  efflux  through  passive  pathway  under  the  inhibition 
of  Na-K  Pase  and  Na-K  cotransport.
Values  are  mean ± SD  of  10  rats
*  V a l u e s  i n  t h e  s a m e  r o w  n o t  s h a r i n g  t h e  s a m e  s u p e r s c r ip t  d i f f er  (p<0.05)
Table 6. Supplementation effects of simvastatin, CoQ10 and green tea to 
cholesterol based diet on liver and PRP TBARS production
Control Statin Statin+
CoQ10
Statin+
Green tea
Cholesterol based diet
TBARS
Liver (µmole/g)* 1.58 ± 0.03
ab 1.86 ± 0.02
a 1.48 ± 0.01
ab 1.32 ± 0.01
b
PRP (µmole/ℓ)* 0.10 ± 0.02
a 0.11 ± 0.01
a 0.06 ± 0.01
b 0.06 ± 0.02
b
PRP  stands  for  platelet  rich  plasma
V a l u e s  a r e  m e a n±S D  o f  1 0  r a t s
*  Values  in  the  same  row  not  sharing  the  same  superscript  differ  (p＜0.05)
of the control and green tea was significant (p<0.05). The 
simvastatin treatment somewhat decreased plasma and liver 
triglyceride without affecting plasma or liver cholesterol. Green 
tea increased HDL-cholesterol and decreased the liver levels of 
total cholesterol and triglyceride.
Whole blood platelet aggregation
Platelet aggregation (Table 4) of both the initial slope and the 
maximum was not statistically different among groups, but the 
group with green tea was tended to be higher in initial slope 
and lower in the maximum compared with other groups.
Hemolysis and erythrocyte Na leak 
Hemolysis and erythrocyte Na leak are shown in Table 5. 
Hemoysis was increased in all groups with simvastatin compared 
to the control, but was not statistically significant. Intracellular 
Na of group with green tea was significantly higher than control 
or statin group (p<0.05). Na leak in intact cells was significantly 
decreased in the statin group compared with control (p<0.05). 
Na leak in AAPH treated cells was also significantly reduced 
in the statin group compared with the control and group with 
CoQ10 (p<0.05). Increase in Na leak after treating AAPH was 
the highest in the group with CoQ10. Na leak in intact cell was 
not correlated with intracellular Na.
Liver and PRP TBARS production
Liver TBARS production (Table 6) was increased in the statin 
group and decreased in the group with green tea, but no statistical 
difference among groups. TBARS production in platelet rich 
plasma was significantly decreased in groups with CoQ10 and 
green tea compared with the control and statin groups (p<0.05).
Discussion
Akiba  et al. (1999) observed that NK-104, a HMG CoA 
reductase inhibitor suppressed body weight gain or decreased 
body weight with dose of 50 mg/kg in rats. Chronic pravastatin 
plus captopril treatment decreased weight gain, improving lipid 
profile and insulin resistance (Villa et al., 1998). Farmer et al. 
(2007) reported that a significant reduction of weight and 
total-cholesterol was observed in rosuvastatin-treated wild type 
mice with the reduced number of cells in the hippocampus 
labeled with glial fibrillary acidic protein (GFAP) where 
rosuvastatin may function in decreasing appetite. In the present 
study, the group with simvastatin decreased weight gain without 
reducing food intake. CoQ10 increased food intake, while green 
tea increased food efficiency ratio, both increasing weight gain 
in statin treated rats. Unlike green tea extract which showed 
antiobese effect in our preliminary experiment, green tea powder 
gave a normal weight gain in this experiment, which suggest 
green tea cellulose may help with weight gain increasing FER.
Hypochoelsterolmic effects of statin have been reported in 
human and animal studies. Fluvastatin, 80 mg daily for 8 weeks 
reduced LDL cholesterol by 35% in patients with type II 302 Statin and antioxidant CoQ10
hypercholesterolemia (Scharnagl et al., 2006). Saito et al. (2003) 
reported rosuvastatin with daily dose rage of 1-40 mg showed 
a linear response in reduction of total cholesterol and apoli-
poprotein B in hypercholesterolemic patients. Fluvastatin, 3.5 
mg/kg BW decreased plasma total cholesterol and triglyceride 
in mice (Galus et al., 2006) and lovastatin, 5 mg/kg BW or 
pravastatin 2.5 mg/kg BW reduced plasma cholesterol by 36%, 
30% respectively with reduction of HMG CoA reducase by 50% 
and 41% in chow fed dog (Davis et al., 2001). Fluvastatin of 
2 mg/kg BW daily decreased plasma total cholesterol and 
triglyceride with an increased HDL-cholesterol in rabbits 
(Bandoh  et al., 2000). Aggawal et al.(2005) reported that 
atorvastatin at 50mg/100g diet in guinea pigs decreased 35% 
LDL cholesterol and 40% triglyceride with decreased cholesterol 
ester transfer protein (CETP) activity. Unlike these results, 
Sawada et al. (2002) reported that pravastatin (1~100 mg/kg BW) 
in hamsters increased serum cholesterol levels and dose 
dependently decreased serum triglyceride levels, and pravastatin 
at 3.2 and 10 mg/kg increased hepatic HMG-CoA reductase 
activity. The species difference in the metabolic pathway of 
cholesterol and lipoprotein can explain for this discrepancy. 
Approximately 65% of total cholesterol in human is endo-
genously synthesized in extrahepatic tissues (Dieschy et al., 
1993). Fernandez et al. (2004) observed that like humans, guinea 
pigs have moderate rates of hepatic cholesterol synthesis, whereas 
the major site of cholesterol synthesis in rats is the liver, and 
guinea pigs, unlike rats, carries most of cholesterol in LDL and 
upregulation of LDL receptor by statin drug is another way in 
lowering cholesterol in humans and guinea pigs. Intestinal and 
hepatic acyl CoA:cholesterol acyl transferase (ACAT) which are 
not active in rats were inhibited by statin in guinea pigs resulting 
in significant reduction of plasma cholesterol (Fernandez et al., 
2001). Intestinal and hepatic ACAT are known to be involved 
in cholesterol absorption, storage and lipoprotein assembly, 
producing cholesterol ester depleted chylomicron and VLDL 
particles and reducing plasma cholesterol. In present study, 
simvastatin with high dose of 30 mg/kg BW failed to reduce 
plasma and liver total cholesterol with minor reduction of plasma 
and liver triglyceride. Many of enzymes or proteins such as HMG 
CoA reductase, CETP, ACAT, cholesterol 7α hydroxylase and 
more recently apical sodium dependent bile acid transporter 
(ASBT), microsomal transport protein (MTP) are known to be 
involved in metabolic pathway of lipoprotein, and more studies 
at molecular level are needed to clarify the metabolic differences 
between species. Mabuchi et al. (2007) reported CoQ10 supple-
mentation of 100 mg/day did not affect the plasma level of LDL 
cholesterol and triglyceride, but significantly increased HDL 
cholesterol in hypercholesterolemic patients with atorvastatin 
therapy, which agreed with our results in some extent. We assume 
that supplemented CoQ10 in our study did not exert feedback 
inhibition on HMG CoA reductase in cholesterol synthesis. 
Raederstorff  et al. (2003) reported tea catechin prevents lipid 
absorption, decreasing plasma total cholesterol and triglyceride. 
Green tea powder of 4% in rat had antiobese and hypotriglycemic 
effect without influencing plasma cholesterol (Sayama et al., 
2003). Dietary green tea in the present study significantly 
decreased the liver levels of cholesterol and triglyceride, and the 
increased plasma triglyceride in the group of green tea can be 
explained with the increased secretion of liver triglyceride, 
preventing fatty liver. Liu et al. (1995) observed that increased 
liver triglyceride with decreased plasma triglyceride in hyper-
cholesterolemic rat was attributed to the low secretion of de novo 
synthesized triglyceride, causing fat accumulation in the liver.
Platelet aggregation and its release reaction were affected by 
the condition of oxidative stress (Naseem et al., 1999). The rel-
ease reaction in the process of aggregation induces the 2nd phase 
of aggregation where the released ADP and serotonin potentiate 
platelet aggregation. Pravastatin treatment significantly reduced 
LDL-cholesterol and inhibited ADP induced platelet aggregation 
and TXB2 synthesis in Chinese patients with primary hyper-
cholesterolemia (Dajani et al., 2002). Haramaki et al. (2007) 
reported that in vitro study fluvastatin dose-dependently inhibited 
platelet aggregation and decreased platelet-derived nitric oxide 
(PDNO) release. Statin may function on platelet aggregation thro-
ugh its action on cholesterol metabolism and membrane lipids, 
since hypersensitivity of platelet is associated with hyperchole-
sterolemic condition. CoQ10 in form of ubiquinol may reduce 
oxidative stress which leads to hypersensitivity of platelets. Green 
tea suppressed the collagen induced platelet aggregation inde-
pendent manner of cholesterol lowering. In present study, platelet 
aggregation in initial slope and maximum aggregation was not 
affected with statin or CoQ10, but green tea tended to decrease 
the initial slope and increase the maximum aggregation which 
is associated with the platelet survival after aggregation. 
Atorvastatin decreased cholesterol contents in erythrocyte 
membrane decreasing cholesterol/phospholipid ratio, giving 
membrane stability with increased Na-K ATPase in guinea pig 
(Uyuklu et al., 2007). Cholesterol content of membrane is one 
of determinant factors for membrane fluidity. Higher concen-
trations of membrane cholesterol and TBARS and lower activity 
of Na-K ATPase were observed in erythrocyte of patient with 
hyperlipidemia, and pravastatin reversed or lessened this 
condition independent manner of cholesterol lowering effects 
(Broncel  et al., 2007). In the present study, simvastatin, a 
lipophilic statin, can cross membrane layers and act on cont-
rolling membrane cholesterol and membrane stability resulting 
in decreased passive diffusion in intact cells. CoQ10 and green 
tea somewhat increased the reduced passive Na leak in intact 
cells of the statin group. The magnitude of Na leak of intact 
cells is theoretically correlated with intracellular Na, but the 
control group had the highest passive Na leak with the lowest 
intracellular Na concentration. Leak increase (∆ Na leak) after 
treated with AAPH was the highest in the group with CoQ10, 
which can be interpreted as the more membrane damage. CoQ10 
may not be effective in stabilizing membranes. Broncel et al. 
(2006) suggested statin induced antioxidant enzymes such as Yang Hee Kim et al. 303
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Fig. 1. Microscopic appearance of liver tissue (×400)
CAT, SOD and glutathione peroxidase, reducing plasma lipids 
and TBARS production. Atorvastatin reactive metabolite (ATM) 
blocks membrane cholesterol from oxidative stress decreasing 
lipid peroxidation in LDL (Mason et al., 2006). Plant antioxidant 
reduced platelet superoxide and TXA2 production (Ryszawa et 
al., 2006). CoQ10 and green tea decreased TBARS production 
in liver and PRP, but CoQ10 was not effective in protecting 
membrane from oxidative stress. Erythrocyte Na leak is Na efflux 
through lipid bilayer of cell membrane in the manner of passive 
diffusion by concentration gradient. Upon exposure to AAPH 
radical generating system, Na leak would increase with the extent 
of membrane damage. TBARS is a product of membrane lipid 
peroxidation, and TBARS production will be correlated with leak 
increase. The leak difference between intact cells and AAPH 
treated cells was the highest in rats with CoQ10, coenzyme Q10 
in the present study did not prevent membrane damage, but it 
was effective in reducing TBARS production in PRP. Antioxidant 
effect of green tea was obvious, but coenzyme Q10 did not show 
consistent effects. More studies are needed to elucidate the 
mechanism of CoQ10 functioning as antioxidant.
We examined the liver tissue for some damages from the high 
dose of statin treatment. Since all groups of experimental animals 
received a cholesterol diet, there was no difference among groups 
on gross observation. Livers from all groups were large with 
LW/BW ratio raging 4.2-4.3 compared with the rough value of 
2.5 in normal rats and the liver tissue was quite hypochromic, 
which can be defined as fatty liver. On microscopic observation 
(Figure 1), liver specimens from groups of CoQ10 and green 
tea showed less fat drops than those from the control and statin 
group, which suggests that CoQ10 and green tea alleviate fatty 
liver in some extent in hypercholesterolemic rats. 
In the present study, simvastatin treatment in hyperchole-
sterolemic rats did not show a cholesterol lowering effect, but 
showed a hypolipidemic effect. CoQ10 supplementation to the 
statin diet did not affect plasma and liver levels of cholesterol 
and triglyceride. Green tea supplementation to the statin diet 
prevented the liver fat accumulation caused by high cholesterol 
diet. CoQ10 and green tea did not affect platelet aggregation 
and membrane Na leak, but reduced TBARS production in liver 
and platelet rich plasma.
The beneficial effect of CoQ10 and green tea as an antioxidant 
may not be further discussed unless CoQ10 depletion with statin 
treatment is verified in rat model. Numerous clinical trials have 
been done on CoQ10 supplementation at dose of 90 mg-600 
mg/day depending on the clinical purpose in patients with statin 
therapy, mostly showing beneficial effects of statin. Studies rep-
orted that CoQ10 supplementation recovers the depleted plasma 
CoQ10 following statin therapy and alleviated myopathic and 
myalgic symptoms. The council of responsible nutrition, USA 
reported that a daily dose of 1200 mg/day CoQ10 was tolerated 
in most patients with statin therapy, suggesting the observed 
safety level (OSL) upper 1200 mg/day. However, as long as there 
are reports of nausea and other adverse gastrointestinal effects 
in individuals taking CoQ10 at the low level as 60 mg-200 
mg/day, extra CoQ10 supplementation may not be yet recom-
mendable to the general population without statin therapy 
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